Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06676852 · ClinicalTrials.gov registry record · NA
Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation
A NA study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT06676852: Recruiting NA study, sponsored by Massachusetts General Hospital.
NCT06676852 is a NA study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06676852, a NA study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
Primary PC - or training HCT clinicians to deliver PC domains as part of routine practice - is an alternative model of supportive care. We have developed Sentinel, a primary PC intervention for HCT clinicians and patients. This study will assess Sentinel's feasibility and acceptability.
Interventions
- BEHAVIORAL Primary palliative care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2027-03-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06676852
The ClinicalTrials.gov registry entry for NCT06676852 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Primary palliative care is the first listed.
NCT06676852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06676852 about?
NCT06676852 is a clinical study titled "Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation". Primary PC - or training HCT clinicians to deliver PC domains as part of routine practice - is an alternative model of supportive care. We have developed Sentinel, a primary PC intervention for HCT clinicians and patients. This study will assess Sentinel's feasibility and acceptability.
What is the current status of trial NCT06676852?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-01-05. Estimated completion is 2027-03-30.
What interventions are being tested in trial NCT06676852?
The interventions under investigation include: Primary palliative care (BEHAVIORAL).
Who is sponsoring clinical trial NCT06676852?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.